Welcome to LookChem.com Sign In|Join Free

CAS

  • or

14756-24-2

Post Buying Request

14756-24-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

14756-24-2 Usage

Description

DiMNF (14756-24-2) is a selective aryl hydrocarbon receptor (AHR) modulator (SAhRM). It exhibits antiinflammatory activity including suppression of cytokine-mediated acute phase genes through dissociation of non-dioxin-response element (DRE) AHR activity from DRE-dependent xenobiotic gene expression.1?DiMNF represses the cytokine-mediated induction of CD55 and therefore may have therapeutic potential in regulating the immune response to tumor formation.2?Represses estrogen-inducible transcription.3

Uses

Different sources of media describe the Uses of 14756-24-2 differently. You can refer to the following data:
1. 3',4'-Dimethoxy-α-naphthoflavone (DiMNF) is a potent and selective aryl hydrocarbon receptor (AHR) modulator (SAhRM). Studies show that DiMNF suppresseses cytokine-mediated complement factor gene expression through selective activation of the Ah receptor. DiMNF has therapeutic potential in regulating the immune response to tumor formation.
2. 3'',4''-Dimethoxy-α-naphthoflavone (DiMNF) is a potent and selective aryl hydrocarbon receptor (AHR) modulator (SAhRM). Studies show that DiMNF suppresseses cytokine-mediated complement factor gene expression through selective activation of the Ah receptor. DiMNF has therapeutic potential in regulating the immune response to tumor formation.

References

1) Murray?et al. (2011),?Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3’,4’-dimethoxy-α-naphthoflavone;? Mol. Pharmacol.,?79?508 2) Narayanan?et al. (2012),?Selective aryl hydrocarbon receptor modulator-mediated repression of CD55 expression induced by cytokine exposure;? J. Pharmacol. Exp. Ther.,?342?345 3) Labrecque?et al. (2012),?Distinct roles for aryl hydrocarbon receptor nuclear translocator and ah receptor in estrogen-mediated signaling in human cancer cell lines;? PLoS One,?7(1)?e29545

Check Digit Verification of cas no

The CAS Registry Mumber 14756-24-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,7,5 and 6 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 14756-24:
(7*1)+(6*4)+(5*7)+(4*5)+(3*6)+(2*2)+(1*4)=112
112 % 10 = 2
So 14756-24-2 is a valid CAS Registry Number.
InChI:InChI=1/C21H16O4/c1-23-18-10-8-14(11-20(18)24-2)19-12-17(22)16-9-7-13-5-3-4-6-15(13)21(16)25-19/h3-12H,1-2H3

14756-24-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (SML0079)  DiMNF  ≥98% (HPLC)

  • 14756-24-2

  • SML0079-5MG

  • 1,987.83CNY

  • Detail
  • Sigma

  • (SML0079)  DiMNF  ≥98% (HPLC)

  • 14756-24-2

  • SML0079-25MG

  • 7,991.10CNY

  • Detail

14756-24-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(3,4-dimethoxyphenyl)benzo[h]chromen-4-one

1.2 Other means of identification

Product number -
Other names 2-(3,4-Dimethoxyphenyl)-benzo[h]chromen-4-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:14756-24-2 SDS

14756-24-2Downstream Products

14756-24-2Relevant articles and documents

Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2

Juvale, Kapil,Stefan, Katja,Wiese, Michael

, p. 115 - 126 (2013/10/01)

Multidrug resistance (MDR) often leads to a failure of cancer chemotherapy. Breast Cancer Resistance Protein (BCRP/ABCG2), a member of the superfamily of ATP binding cassette proteins has been found to confer MDR in cancer cells by transporting molecules with amphiphilic character out of the cells using energy from ATP hydrolysis. Inhibiting BCRP can be a solution to overcome MDR.We synthesized a series of flavones, 7,8-benzofl avones and 5,6-benzo flavones with varying substituents at positions 3, 3′ and 4′ of the (benzo)fl avone structure. All synthesized compounds were tested for BCRP inhibition in Hoechst 33342 and pheophorbide A accumulation assays using MDCK cells expressing BCRP. All the compounds were further screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity by calcein AM accumulation assay to check the selectivity towards BCRP. In addition most active compounds were investigated for their cytotoxicity. It was observed that in most cases 7,8-benzoflavones are more potent in comparison to the 5,6-benzoflavones. In general it was found that presence of a 3-OCH3 substituent leads to increase in activity in comparison to presence of OH or no substitution at position 3. Also, it was found that presence of 3′,4′-OCH3 on phenyl ring lead to increase in activity as compared to other substituents. Compound 24, a 7,8-benzoflavone derivative was found to be most potent being 50 times selective for BCRP and showing very low cytotoxicity at higher concentrations.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 14756-24-2